Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 Monotherapy is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 Monotherapy is a randomized open-label crossover study comparing the final fixed dose of oral ASTX030 to SC azacitidine. Phase 1 Combination Therapy is an open-label, multicenter, randomized, exploratory study comparing ASTX030 and SC azacitidine in combination with venetoclax in participants with treatment-naïve AML. Phase 2 Combination Therapy is an open-label, single arm, study evaluating the efficacy, safety, pharmacokinetics (PK), and drug interactions of ASTX030 in combination with venetoclax in participants with treatment-naïve AML. The duration of this multi-phase study is approximately 8 years.
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
This trial is no longer recruiting — here are similar active trials
Matched by cancer type/biomarker, currently recruiting.
The aim of the study is to test the effect of tDCS stimulation on upper and lower limb function in neurological patients and to reduce pain in gynaecological patients. And the impact of tDCS stimulation on patients' quality of life. Standardised questionnaires will be used for pre- and post-stimulation evaluation.
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
About the trial
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with anticancer therapies in participants with selected advanced or metastatic solid tumors. This study will consist of 2 parts. In Part 1, INCB123667 will be administered as monotherapy and in Part 2, INCB123667 will be administered in combination with anticancer therapies of interest. Each part will comprise a dose escalation portion (Parts 1a and 2a, respectively) and a dose-expansion portion (Parts 1b and 2b, respectively).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Przewidywany czas życia dłuższy niż 12 tygodni.
- •Dobry ogólny stan zdrowia (punktacja 0 lub 1 w skali ECOG).
- •Choroba, która postępowała mimo wcześniejszego standardowego leczenia, lub brak tolerancji na standardowe leczenie, lub brak dostępnych opcji leczenia.
- •Dostępna próbka guza z wcześniejszego badania lub zgoda na pobranie próbki guza przed leczeniem i w jego trakcie.
- •Badanie ma dwie części: pierwsza to podawanie INCB123667 samodzielnie, druga to podawanie go w połączeniu z innymi terapiami przeciwnowotworowymi.
- •W drugiej części badania lek będzie stosowany w połączeniu z innymi terapiami w określonych typach raka piersi (HR+/HER2-), nowotworów jajnika, jajowodu, otrzewnej oraz innych nowotworów litych.
✗ Disqualifies
- •Przeszłość lub obecność istotnych problemów z sercem, które nie są pod kontrolą.
- •Obecność nieprawidłowości w zapisie EKG, które lekarz uzna za istotne.
- •Obecność przewlekłej lub aktywnej choroby zakaźnej wymagającej leczenia antybiotykami, lekami przeciwgrzybiczymi lub przeciwwirusowymi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 21, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (41)
City of Hope Medical Center
Duarte, United States
City of Hope-Lennar Foundation Cancer Center
Irvine, United States
Valkyrie Clinical Trials
Los Angeles, United States
Rocky Mountain Cancer Centers-Sky Ridge
Lone Tree, United States
Yale Cancer Center
New Haven, United States
Mount Sinai Medical Center Comprehensive Cancer Center
Miami Beach, United States
Emory University
Atlanta, United States
Memorial Sloan Kettering Cancer Center
New York, United States
New York Presbyterian/Weill Cornell
New York, United States
Ny Cancer and Blood Specialists
Shirley, United States
Carolina Bio-Oncology Institute, Pllc
Huntersville, United States
University of Pennsylvania Abramson Cancer Center
Philadelphia, United States
University of Pittsburgh Cancer Institute Cancer Services
Pittsburgh, United States
Allegheny Health Network
Pittsburgh, United States
Tennessee Oncology
Nashville, United States
Texas Oncology-Fort Worth South Henderson
Fort Worth, United States
Virginia Cancer Institute
Fairfax, United States
University of Wisconsin
Madison, United States
Institut Bergonie
Bordeaux, France
Centre Leon Berard
Lyon, France
Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole
Toulouse, France
Institut Gustave Roussy
Villejuif, France
Fondazione Irccs Istituto Nazionale Dei Tumori
Milan, Italy
Istituto Nazionale Tumori Irccs Fondazione Pascale
Naples, Italy
Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore
Rome, Italy
Irccs Istituto Clinico Humanitas
Rozzano, Italy
Centro Ricerche Cliniche Di Verona
Verona, Italy
Aichi Cancer Center Hospital
Aichi, Japan
National Cancer Center Hospital East
Chiba-ken, Japan
Saitama Medical University International Medical Center
Hidaka-shi, Japan
National Cancer Center Hospital
Tokyo, Japan
The Cancer Institute Hospital of Jfcr
Tokyo, Japan
Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis
Amsterdam, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
Panoncology Trials Pan American Center For Oncology Trials, Llc
Rio Piedras, Puerto Rico
Oncological Institute of Southern Switzerland
Bellinzona, Switzerland
Inselspital Universitatsklinik Fur Medizinische Onkologie
Bern, Switzerland
Centre Hospitalier Universitaire Vaudois (Chuv)
Lausanne, Switzerland
Guys Hospital
London, United Kingdom
Imperial College Healthcare Nhs Trust - Hammersmith Hospital
London, United Kingdom
Northern Centre For Cancer Care
Newcastle upon Tyne, United Kingdom
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.